Search Results for "content marketing"

Michael Pietrack

Leadership Lab: 10 Ways Executives Can Stay Visible, Valuable Between Jobs

Oct 22^nd • 5 mins read

Michael Pietrack

Leadership Lab: 5 Steps for Building Your Personal Brand

Aug 19^th • 5 mins read

Michael Pietrack

Managing Emotions After Being Downsized

Oct 21^st • 5 mins read

Michael Pietrack

How to Elevate Your Career: Go from Individual Contributor to People Leader

Jul 24^th • 5 mins read

Tom Caravela

Mastering the First Impression

Jan 29^th • 2 mins read

Tom Caravela

Interview Differentiator-Be a Story Teller

Mar 22^nd • 1 min read

Tom Caravela

MSL Retention – What Matters Most

Mar 15^th • 2 mins read

Tom Caravela

Resume Writing and Editing Tips for Pharma Professionals

Aug 8^th • 1 min read

Bridget Rasmusson

6 Tips to Ace Your Next MSL Interview!

Sep 28^th • 1 min read

Tom Caravela

7 High-Cost Interview Mistakes that are Easy to Avoid

Jul 28^th • 1 min read

Tom Caravela

INTENTION: The Key to Achieving Your Goals

Jan 21^st • 1 min read

Tom Caravela

MSL Evolution: New Trends and Titles That May Emerge

Apr 5^th • 1 min read

Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Apr 7^th • 12 mins read

Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Sep 14^th • 4 mins read

Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Nov 20^th • 12 mins read

Muneera Al Hussain

Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis

Jun 24^th • 3 mins read

Eric Q. Konnick

The regulatory landscape of precision oncology laboratory medicine in the United States - Perspective on the past 5 years and considerations for future regulation

May 22^nd • 8 mins read

Tanja Cufer, Tudor E. Ciuleanu, Peter Berzinec, Gabriela Galffy, Marko Jakopovic, Jacek Jassem, Dragana Jovanovic, Zhasmina Mihaylova, Gyula Ostoros, Christiane Thallinger, Milada Zemanova, Christoph Zielinski

Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

Nov 24^th • 10 mins read

Christopher A. Busch, MSC; Johannes Krisam, PhD; Meinhard Kieser, PhD

A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials—A Simulation Study

Jun 28^th • 30 mins read

Natansh D. Modi, BPharm; Ahmad Y. Abuhelwa, PhD; Ross A. McKinnon, PhD

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration

Jul 28^th • 20 mins read

Navigation

Results for 'content marketing'

Leadership Lab: 10 Ways Executives Can Stay Visible, Valuable Between Jobs

Leadership Lab: 5 Steps for Building Your Personal Brand

Managing Emotions After Being Downsized

How to Elevate Your Career: Go from Individual Contributor to People Leader

Mastering the First Impression

Interview Differentiator-Be a Story Teller

MSL Retention – What Matters Most

Resume Writing and Editing Tips for Pharma Professionals

6 Tips to Ace Your Next MSL Interview!

7 High-Cost Interview Mistakes that are Easy to Avoid

INTENTION: The Key to Achieving Your Goals

MSL Evolution: New Trends and Titles That May Emerge

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Accelerated drug approvals in oncology: Pros and cons

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis

The regulatory landscape of precision oncology laboratory medicine in the United States - Perspective on the past 5 years and considerations for future regulation

Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials—A Simulation Study

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration

Related Topics